Asia Pacific Patient Derived Xenografts/PDX Models Market (2025-2030)
The Asia Pacific Patient Derived Xenografts/PDX Models Market was valued at $50.3 Million in 2025 and projected to reach to $83.1 Million by 2030, representing a compound annual growth rate of 10.6%. The Asia Pacific PDX Models Market is positioned for sustained growth as the region strengthens its position in personalized medicine and oncology research.
| Market Size in | USD 26.32 MN |
| Market Forecast in | |
| CAGR | |
| Forecast Period | |
| Units Considered | Value (USD MN) |
Asia Pacific Patient Derived Xenografts/PDX Models Market Trends and Insights
- Asia Pacific is emerging as a critical hub for personalized medicine and oncology research, driven by increasing investments in biotechnology infrastructure and rising adoption of precision medicine approaches across the region.
- The market growth in Asia Pacific reflects heightened demand for advanced preclinical models that enable more accurate drug efficacy and toxicity testing. Asia Pacific's PDX models market is supported by expanding pharmaceutical and contract research organization (CRO) capabilities, particularly in countries with strong biotech ecosystems.
- The region's growing patient population and prevalence of cancer have accelerated the need for patient-derived models in Asia Pacific, enabling researchers to develop more effective therapeutic strategies.
- Between 2025 and 2030, Asia Pacific is expected to capture significant market share as regulatory frameworks mature and funding for translational research increases. Key drivers propelling Asia Pacific's market include rising R&D expenditures, collaboration between academic institutions and industry players, and increasing awareness of personalized oncology solutions.
- Asia Pacific's competitive advantage lies in cost-effective research capabilities and access to diverse patient populations, positioning the region as an attractive destination for global PDX model development and validation..
Key Market Statistics
- CAGR (2025-2030) 10.6% CAGR
- Market Size, 2025 ~USD 50.3 Million
- Forecast, 2030 ~USD 83.1 Million
- Geography Asia Pacific
Asia Pacific Patient Derived Xenografts/PDX Models Market Overview
Rapid Market Growth :
Asia Pacific PDX Models Market is expanding at 10.6% CAGR, growing from $50.3 million in 2025 to $83.1 million by 2030, outpacing many mature markets in adoption and investment.
China's Market Leadership :
China dominates the Asia Pacific region with $34.2 million market valuation, driven by substantial government funding for cancer research and biotechnology infrastructure development across major research institutions.
Japan's Precision Medicine Focus :
Japan represents the second-largest market at $24.1 million, leveraging advanced pharmaceutical R&D capabilities and strong adoption of personalized oncology approaches in clinical practice.
Emerging Biotech Ecosystem :
India and South Korea are emerging as growth catalysts with $7 million and $6.4 million respectively, supported by increasing CRO investments and rising demand for cost-effective PDX model development services.
Asia Pacific Patient Derived Xenografts/PDX Models Market Dynamics
- Government initiatives across China, Japan, and India are accelerating biotechnology infrastructure investments, while pharmaceutical companies increasingly establish regional R&D centers to leverage cost advantages and local expertise.
- The region's growing patient population and rising cancer incidence rates are driving demand for patient-derived xenograft models in drug development and clinical research. Key growth drivers include expanding collaborations between academic institutions and pharmaceutical companies, increasing adoption of precision medicine frameworks, and rising venture capital funding for biotech startups.
- Asia Pacific's competitive advantage in manufacturing and research services is attracting global pharmaceutical companies to establish PDX development partnerships.
- By 2030, the region is expected to become a critical hub for personalized oncology research, with emerging markets contributing significantly to the overall market expansion..
Related Ecosystem
Biotechnology
- Reagents
- Polymerase Chain Reaction (PCR)
- Stem Cells
- Assay Kits
- Flow Cytometers
- Thermo Fisher Scientific Inc.
- Merck KGaA
- Danaher Corporation
- Agilent Technologies, Inc.
- Bio-Rad Laboratories, Inc.
Pharmaceuticals
- Bioreactors
- Analytical Testing
- Bioanalytical Testing Services
- Cell Counters
- Data Management Services
- Merck KGaA
- Thermo Fisher Scientific Inc.
- SANOFI
- NOVARTIS
- Pfizer Inc.
Key Takeaways
- Asia Pacific's PDX models market is valued at $50.3 million in 2025 and will grow to $83.1 million by 2030, representing a 10.6% CAGR.
- Asia Pacific is becoming a preferred destination for PDX research due to cost-effective capabilities, diverse patient populations, and expanding biotech infrastructure.
- Rising investments in oncology research and precision medicine adoption are driving demand for patient-derived xenograft models across Asia Pacific.
- Asia Pacific's regulatory maturation and increased pharmaceutical R&D spending will accelerate PDX model adoption through 2030.
Patient Derived Xenografts/PDX Models Market Report Scope
| Report Metric | Details |
|---|---|
| Base Year | 2025 |
| Fastest Growing Segment | ORTHOTOPIC IMPLANTATION (Implantation Method) |
| Forecast Period | 2025–2030 |
| Growth Rate | CAGR of 12.5% from 2025 to 2030 |
| Largest Segment | PDX MODELS (Model Type & Service) |
| Market Size Base Year (Billions) | ~USD 0.37 (2025) |
| Revenue Forecast (Billions) | ~USD 0.66 (2030) |
| Segments Covered | Model Type & Service, Type, Implantation Method |
Asia Pacific Patient Derived Xenografts/PDX Models Market Report Segmentation
3 segment dimensions are covered across the global market.
By Model Type & Service
- Pdx Models
- Pdx Services
By Type
- Cryopreservation Services
- Model Characterization Services
- Model Creation & Expansion Services
- Mouse Model
- Other Pdx Services
- Rat Model
By Implantation Method
- Orthotopic Implantation
- Other Implantation Methods
- Subcutaneous Implantation
Target Audience
- Pharmaceutical Companies : Evaluate Asia Pacific as a strategic hub for PDX model development and oncology research, with insights on cost-effectiveness, regulatory pathways, and partnership opportunities with regional CROs and research institutions.
- Biotechnology & CRO Firms : Understand market demand for PDX services across Asia Pacific, competitive positioning, pricing strategies, and opportunities to establish or expand regional operations in high-growth markets like China and India.
- Research Institutions & Universities : Identify funding opportunities, collaborative research initiatives, and infrastructure development trends across Asia Pacific academic centers to enhance PDX model capabilities and attract pharmaceutical partnerships.
- Investment & Venture Capital Firms : Assess investment potential in Asia Pacific biotech startups specializing in PDX models, with market sizing, growth projections, and competitive analysis to guide portfolio decisions and funding strategies.
- Healthcare Policy & Government Bodies : Leverage market intelligence to inform biotechnology policy development, research funding allocation, and infrastructure investment decisions to strengthen Asia Pacific's position in personalized medicine innovation.
Key Companies in the Asia Pacific Patient Derived Xenografts/PDX Models Market
| Company | HQ | Ownership | Strongest segments |
|---|---|---|---|
| CHARLES RIVER LABORATORIES | United States | Public Company | Research Models and Services,Discovery and Safety Assessment,Manufacturing Solutions, |
| THE JACKSON LABORATORY | United States | Foundation/Charitable Institution | Mouse breeding & colony management,Phenotyping, efficacy testing & study-ready induced models,Genetic research services & bioinformatics, |
| INOTIV | United States | Public Company | Research Models and Services (RMS),Discovery and Safety Assessment (DSA) Services,BASi Scientific Instruments and Software, |
| JSR CORPORATION | Japan | Private Company | Digital Solutions (lithography, photoresists, CMP, display, 3D printing),Plastics (ABS, AES, AS, ASA resins),Life Sciences (diagnostics, reagents, bioprocess, drug discovery support), |
| GENOWAY | France | Public Company | Custom mouse models (KO/KI, humanized, immune checkpoint),Custom rat models (KO/KI, immunodeficient, reconstituted),Custom cell lines (KO/KI, reporter, inducible), |
| BIOCYTOGEN PHARMACEUTICALS CO., LTD. | China | Public Company | Gene-Editing Services,Pharmacological Efficacy and Toxicology Services,Model Animals, |
| CHAMPIONS ONCOLOGY, INC. | United States | Public Company | Tumorgraft-based translational oncology services,Personalized cancer care / patient-specific Tumorgraft programs,Lumin Bioinformatics and data-driven software, |
| PHARMARON | China | Public Company | Laboratory Services,Chemical and Formulation Process Development and Manufacturing Services (Small Molecule CDMO),Clinical Research Services, |
| SYNGENE INTERNATIONAL LIMITED | India | Public Company | Discovery services (chemistry and biology),Development services (preclinical, CMC, clinical development),Manufacturing (API and drug product, including biologics), |
| LABCORP | United States | Public Company | Routine and preventive diagnostics (chemistry, hematology, urinalysis, wellness),Specialty and esoteric testing (genetic, oncology, infectious disease, women’s health),Biopharma laboratory services and clinical trial testing, |
| EUROFINS SCIENTIFIC | Luxembourg | Public Company | Food and Feed Testing,Environmental Testing,Biopharma Testing and Services, |
CHARLES RIVER LABORATORIES
Charles River Laboratories is a public company founded in 1947 and headquartered in the United States. With 19,000 employees, it operates as a major provider of preclinical and clinical laboratory services.
THE JACKSON LABORATORY
The Jackson Laboratory is a foundation-based charitable institution founded in 1929 in the United States. The organization employs 2,100 staff members and focuses on genetic research and related scientific services.
INOTIV
INOTIV is a public company founded in 1974 and based in the United States. The company operates with 1,996 employees and provides research and development services.
JSR CORPORATION
JSR Corporation is a private company founded in 1948 and headquartered in Japan. With 7,997 employees, the company operates across multiple business segments.
GENOWAY
GENOWAY is a public company founded in 1999 and based in France. The organization employs 157 staff members and operates in the biotechnology sector.
BIOCYTOGEN PHARMACEUTICALS CO., LTD.
BIOCYTOGEN PHARMACEUTICALS CO., LTD. is a public company founded in 2008 and based in China. The company employs 1,443 staff members and operates in the pharmaceutical and biotechnology sectors.
CHAMPIONS ONCOLOGY, INC.
Champions Oncology, Inc. is a public company founded in 1985 and based in the United States. The company employs 214 staff members and operates in the oncology research and services sector.
PHARMARON
PHARMARON is a public company founded in 2004 and based in China. With 25,088 employees, the company provides drug discovery and development services.
SYNGENE INTERNATIONAL LIMITED
Syngene International Limited is a public company founded in 1993 and headquartered in India. The organization employs 6,692 staff members and provides integrated drug discovery and development services.
LABCORP
LabCorp is a public company founded in 1995 and based in the United States. With 66,385 employees, it operates as a major provider of clinical laboratory and diagnostic services.
EUROFINS SCIENTIFIC
Eurofins Scientific is a public company founded in 1987 and headquartered in Luxembourg. The organization employs 65,694 staff members and provides laboratory testing and analytical services across multiple industries.
Countries within Asia Pacific - compare and drill down
| Country | 2025 size (native) |
|---|---|
| China | USD 34.2 Million |
| Japan | USD 24.1 Million |
| India | USD 7 Million |
| South Korea | USD 6.4 Million |
| Australia | USD 4.1 Million |
| Rest Of Asia Pacific | USD 7.4 Million |
Country market size visualization
Reasons to Buy this Report
- Regional Market Segmentation : Gain detailed insights into individual Asia Pacific markets including China ($34.2M), Japan ($24.1M), India ($7M), and South Korea ($6.4M) with country-specific growth trajectories and market dynamics.
- Competitive Landscape Analysis : Understand the competitive positioning of PDX model providers across Asia Pacific, including emerging players in India and established leaders in Japan, with strategic recommendations for market entry and expansion.
- Investment Opportunity Assessment : Identify high-growth opportunities in emerging Asia Pacific markets with lower market penetration, supported by increasing government funding and pharmaceutical company investments in regional R&D centers.
- Regulatory & Reimbursement Insights : Access comprehensive analysis of regulatory frameworks, approval pathways, and reimbursement models specific to Asia Pacific countries, enabling informed market strategy development.
- Strategic Partnership Opportunities : Discover collaboration potential with academic institutions, CROs, and biotech companies across Asia Pacific, with detailed mapping of key stakeholders and partnership models in the region.
Frequently asked questions
What is the current market size of PDX models in Asia Pacific?
The Asia Pacific Patient Derived Xenografts/PDX Models Market was valued at $50.3 million in 2025 and is expected to grow to $83.1 million by 2030.
What is the projected growth rate for Asia Pacific's PDX models market?
Asia Pacific's PDX models market is projected to grow at a compound annual growth rate (CAGR) of 10.6% from 2025 to 2030.
Why is Asia Pacific becoming a hub for PDX model development?
Asia Pacific offers cost-effective research capabilities, access to diverse patient populations, expanding biotech infrastructure, and increasing pharmaceutical R&D investments, making it an attractive region for PDX model development.
What factors are driving growth in Asia Pacific's PDX models market?
Key drivers include rising oncology research investments, adoption of precision medicine, regulatory framework maturation, collaboration between academic and industry players, and growing prevalence of cancer in the region.
Which countries in Asia Pacific are leading PDX model adoption?
Countries with strong biotech ecosystems and significant pharmaceutical R&D capabilities, such as China, Japan, South Korea, and Singapore, are leading PDX model adoption in Asia Pacific.
RESEARCH METHODOLOGY
This research study extensively utilized secondary sources, directories, and databases to identify and collect valuable information for analyzing the global PDX model market. In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the growth prospects of the market. The global market size estimated through secondary research was triangulated with inputs from primary research to determine the final market size.
Secondary Research
Secondary research was primarily used to identify and collect information for the comprehensive technical, market-oriented, and commercial study of the PDX model market. The secondary sources used for this study include World Health Organization (WHO), American Association for Cancer Research, American Association for Laboratory Animal Science, EurOPDX, European Animal Research Association, European Society for Medical Oncology, European Association for Cancer Research, Federation for Laboratory of Cell Therapy, International Journal of Non-Communicable Diseases, European Medicines Agency (EMA), Alliance for Regenerative Medicine (ARM); ACS Journals; Corporate filings such as annual reports, SEC filings, investor presentations, and financial statements; research journals; press releases; and trade, business, and professional associations.
Secondary data were collected and analyzed to determine the overall size of the global PDX model market, which was subsequently validated through primary research. These sources were also used to gather key information about major players, market classification, and segmentation based on industry trends, regional/country-level markets, market developments, and technological perspectives.
Primary Research
In-depth interviews were conducted with various primary respondents, including key industry participants, subject-matter experts (SMEs), C-level executives of key market players, and industry consultants, to obtain and verify critical qualitative & quantitative information and assess the market’s prospects. Various primary sources from the supply & demand sides of the market were interviewed to obtain qualitative and quantitative information.
To know about the assumptions considered for the study, download the pdf brochure
Market Size Estimation
The top-down and bottom-up approaches were used to estimate & validate the total size of the PDX model market. These methods were also used extensively to estimate the size of various market segments.
Data Triangulation
After evaluating the overall market size through the market size estimation process, the total market was divided into several segments and subsegments. Data triangulation and market breakdown procedures were used, whenever applicable, to complete the overall market engineering process and obtain precise statistics for all segments and subsegments. The data was triangulated by analyzing various factors and trends from the demand and supply sides.
Market Definition
Patient-derived xenografts (PDXs) are models of cancer where the tissue or cells from a patient’s tumor are implanted into an immunodeficient or humanized mouse. These models have been used to grow cancer tissues after they were removed from a patient. The PDX model is an important tool for cancer research. It is used to study the biology of cancer, test the efficacy of new therapies, and predict the response to therapy in individual patients.
The study offers an in-depth analysis of the PDX model market, examining contemporary market trends and developments, as well as its potential growth from 2025 to 2030. It includes detailed market trends, the competitive landscape, market size, forecasts, and the analysis of the key PDX model product providers.
Stakeholders
- Pharmaceutical & biotechnology companies
- Contract research organizations (CROs)
- Academic & research institutes
- Preclinical and translational research centers
- Life science companies
- Regulatory bodies
- Contract development and manufacturing organizations (CDMOs)
- Cancer research consortia & foundations
- Venture capitalists & strategic investors
- Government associations
- Medical institutions & universities
- Hospitals & clinics
Report Objectives
- To define, describe, and forecast the PDX model market based on implantation method, type, tumor type, application, end user, and region
- To provide detailed information regarding the major factors influencing the market growth (such as drivers, restraints, opportunities, and challenges)
- To strategically analyze micromarkets concerning individual growth trends, prospects, and contributions to the overall PDX model market
- To analyze the opportunities in the market for stakeholders and provide details of the competitive landscape for market leaders
- To forecast the size of the market segments concerning six main regions, namely, North America, Europe, the Asia Pacific, Latin America, the Middle East, and Africa
- To strategically profile the key players in the PDX model market and comprehensively analyze their core competencies and market rankings
- To track and analyze competitive developments such as acquisitions, expansions, agreements, partnerships, and collaborations in the PDX model market
- To benchmark players within the PDX model market using the ‘Company Evaluation Matrix' framework, which analyzes market players based on various parameters within the broad categories of business and product strategy
Get the Full Patient Derived Xenografts/PDX Models Market Report
Full forecast, segment splits, and company analysis for all Patient Derived Xenografts/PDX Models Market.
- Canada Patient Derived Xenografts/PDX Models Market
- US Patient Derived Xenografts/PDX Models Market
- Germany Patient Derived Xenografts/PDX Models Market
- UK Patient Derived Xenografts/PDX Models Market
- France Patient Derived Xenografts/PDX Models Market
- Italy Patient Derived Xenografts/PDX Models Market
- Spain Patient Derived Xenografts/PDX Models Market
- China Patient Derived Xenografts/PDX Models Market
- Japan Patient Derived Xenografts/PDX Models Market
- India Patient Derived Xenografts/PDX Models Market
- Australia Patient Derived Xenografts/PDX Models Market
- South Korea Patient Derived Xenografts/PDX Models Market
- Brazil Patient Derived Xenografts/PDX Models Market
- Mexico Patient Derived Xenografts/PDX Models Market
- UAE Patient Derived Xenografts/PDX Models Market
- Rest Of Europe Patient Derived Xenografts/PDX Models Market
- Rest Of Asia Pacific Patient Derived Xenografts/PDX Models Market
- Rest Of Latin America Patient Derived Xenografts/PDX Models Market
- Kingdom Of Saudi Arabia Patient Derived Xenografts/PDX Models Market
- Rest Of GCC Countries Patient Derived Xenografts/PDX Models Market
Need a Tailored Report?
Customize this report to your needs
Get 10% FREE Customization
Customize This Report